Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?

Eapen V, John G.

Australas Psychiatry. 2011 Jun;19(3):232-5. doi: 10.3109/10398562.2010.539609. Review.

PMID:
21682621
2.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
3.

Management of schizophrenia with obesity, metabolic, and endocrinological disorders.

Monteleone P, Martiadis V, Maj M.

Psychiatr Clin North Am. 2009 Dec;32(4):775-94. doi: 10.1016/j.psc.2009.08.003. Review.

PMID:
19944883
4.

Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story?

Correll CU.

J Clin Psychiatry. 2005 Oct;66(10):1331-2. No abstract available.

PMID:
16259549
5.

Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics.

Park T, Usher K, Foster K.

Int J Ment Health Nurs. 2011 Dec;20(6):428-37. doi: 10.1111/j.1447-0349.2011.00747.x. Epub 2011 May 12.

PMID:
21564457
6.

Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication.

Eapen V, Shiers D, Curtis J.

Aust N Z J Psychiatry. 2013 May;47(5):435-42. doi: 10.1177/0004867412463169. Epub 2012 Oct 9. Review.

PMID:
23047958
7.

Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology.

Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B.

Pharmacol Res. 2015 Nov;101:74-85. doi: 10.1016/j.phrs.2015.07.022. Epub 2015 Jul 26. Review.

PMID:
26218604
8.

[Current views on the metabolic syndrome and the effects of antipsychotic drugs].

Fodor M.

Psychiatr Hung. 2011;26(3):196-200. Hungarian.

PMID:
21799222
9.

[Antipsychotic prescription assessment in general practice: metabolic effects].

Gignoux-Froment F, de Montleau F, Saravane D, Verret C.

Encephale. 2012 Dec;38(6):453-9. doi: 10.1016/j.encep.2011.12.006. Epub 2012 Jan 23. French.

PMID:
23200610
10.

[The metabolic syndrome and antipsychotics in children and adolescents].

Dori N, Green T.

Harefuah. 2011 Oct;150(10):791-6, 814, 813. Review. Hebrew.

PMID:
22111125
11.

When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.

Stein K.

J Am Diet Assoc. 2010 Jul;110(7):992-1001. doi: 10.1016/j.jada.2010.05.015. No abstract available.

PMID:
20630154
12.
13.
14.

Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes.

Edward KL, Rasmussen B, Munro I.

Arch Psychiatr Nurs. 2010 Feb;24(1):46-53. doi: 10.1016/j.apnu.2009.04.009. Epub 2009 Aug 6. Review.

PMID:
20117688
15.

Metabolic complications of schizophrenia and antipsychotic medications--an updated review.

Yogaratnam J, Biswas N, Vadivel R, Jacob R.

East Asian Arch Psychiatry. 2013 Mar;23(1):21-8. Review.

16.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
17.

Schizophrenia, antipsychotics and metabolic disease.

Reynolds GP.

J Psychopharmacol. 2007 Jun;21(4):355-6. No abstract available.

PMID:
17656424
18.

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.

Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ.

Mol Psychiatry. 2012 Mar;17(3):242-66. doi: 10.1038/mp.2011.109. Epub 2011 Sep 6. Review.

PMID:
21894153
19.

[Brazilian Consensus on second-generation antipsychotics and metabolic disorders].

Elkis H, Gama C, Suplicy H, Tambascia M, Bressan R, Lyra R, Cavalcante S, Minicucci W.

Rev Bras Psiquiatr. 2008 Mar;30(1):77-85. Portuguese.

20.

[Psychotropic drugs and diabetes].

Ress C, Tschoner A, Kaser S, Ebenbichler CF.

Wien Med Wochenschr. 2011 Nov;161(21-22):531-42. doi: 10.1007/s10354-011-0004-9. Epub 2011 Jul 29. Review. German.

PMID:
21792529

Supplemental Content

Support Center